In this section you will find information regarding Palatin Technologies’ financial highlights. For your convenience, we provide a library of press releases, events and webcasts, as well as prefiltered links to the EDGAR database.
Palatin Technologies, Inc. (NYSE American: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Palatin’s primary product is Vyleesi, the first and only on demand treatment for premenopausal women with acquired hypoactive sexual desire disorder (HSDD), a condition that affects 1 in 10 premenopausal women.
Information for Investors
Portions of this website contain forward-looking statements that are subject to change. Statements about future expectations of Palatin Technologies, Inc., including statements about our development programs, proposed indications for our product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for various reasons, including but not limited to our ability to fund development of our technology, our ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on our partners for certain development activities, need for regulatory approvals and commercial acceptance of our products, our ability to protect our intellectual property, adoption of new accounting regulations and standards, adverse changes in the securities markets, our ability to comply with continued listing requirements of the NYSE American stock exchange, and other factors discussed in our periodic filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, our Quarterly Reports and other periodic reports. We do not undertake, and specifically disclaim any obligation, to release publicly the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.